Please find enclosed herewith the Outcome of Board Meeting for approval of Standalone and Consolidated Unaudited Results for the Quarter ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab's board, at its meeting on August 13, 2025, approved the unaudited financial results for the quarter ended June 30, 2025 (Q1FY26), along with the limited review report from statutory auditors C. N. Patel & Co. On a standalone basis, revenue from operations fell sharply to Rs. 196.75 lakhs from Rs. 365.99 lakhs in Q1FY25, a drop of roughly 46%. Standalone profit after tax also dropped to Rs. 23.49 lakhs from Rs. 104.99 lakhs a year ago, with EPS at Rs. 0.20 versus Rs. 0.91. On a consolidated basis (which includes subsidiary Naxpar Pharma), revenue grew modestly to Rs. 5,337.55 lakhs from Rs. 5,012.03 lakhs, but PAT slipped to Rs. 327.49 lakhs from Rs. 398.68 lakhs, with EPS of Rs. 2.85 versus Rs. 3.47. The board also fixed the 43rd AGM for September 29, 2025 via video conferencing and appointed M/s HSPN & Associates LLP as the new Secretarial Auditor for five years starting FY 2025-26.
Standalone numbers are weak with a steep revenue and profit decline year-on-year, which is a negative read for the parent-level business; however, the consolidated picture is relatively stable as the subsidiary Naxpar Pharma continues to contribute the bulk of earnings. Investors should watch the standalone trajectory closely as it has now weakened meaningfully.